by Matthew Perrone This image provided by Biogen on Monday, June 7, 2021, shows a vial and packaging for the drug Aduhelm. Drugmaker Biogen has until 2030 to complete a study confirming whether the new drug truly slows the brain-destroying disease. That’s under the terms of the Food and Drug Administration’s conditional approval of the...
